Adherence to hepatitis B virus vaccination at syringe exchange sites

Journal of Urban Health

Volumn 82, Issue 1, 2005, Pages 151-161

  Altice, Frederick L ^a   Bruce, Robert D ^a   Walton, Mary R ^a   Buitrago, Marta I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Access to health care; Adherence; Financial incentives; Hepatitis B virus; Injection drug users; Mobile health care; Prevention; Syringe exchange programs; Vaccination

Indexed keywords

HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; HEALTH CARE ACCESS; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SELF INJECTION; SYRINGE; VACCINATION; VIRUS TRANSMISSION; AGE DISTRIBUTION; BLOOD; DIAGNOSTIC TEST; ETHNOLOGY; EVALUATION; HEALTH SERVICE; ISOLATION AND PURIFICATION; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT COMPLIANCE; STATISTICS; SUBSTANCE ABUSE; UNITED STATES; UTILIZATION REVIEW; VIROLOGY;

ADULT; AGE DISTRIBUTION; CONNECTICUT; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; MALE; MIDDLE AGED; MOBILE HEALTH UNITS; NEEDLE-EXCHANGE PROGRAMS; PATIENT COMPLIANCE; SUBSTANCE ABUSE, INTRAVENOUS; URBAN HEALTH SERVICES;

EID: 23944454951     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/jti016     Document Type: Article

References (56)

1. Office of the Assistant Secretary for Health and Surgeon General. Promoting Health/Preventing Disease-Objectives for the Nation. Washington, DC: US Department of Health and Human Services; 1980.
2. Department of Health and Human Services. Healthy People 2000: National Health Promotion and Disease Prevention Objectives. Washington, DC: US Government Printing Office; 1991:515-516, 518-519, 521-528; DHHS Publication No. (PHS) 91-50212; GPO Stock No. 017-001-0474-0.
3. Department of Health and Human Services. Healthy People 2000: Mid-Course Review and 1995 Revisions. Washington, DC: US Government Printing Office; 1995:121-124, 260-263; GPO Stock No. 017-001-00-526-6.
4. Mast EE, Mahoney FJ, Alter MJ, Margolis HS. Progress toward elimination of hepatitis B virus transmission in the United States. Vaccine. 1998;16:S48-S51.
5. Update: recommendations to prevent hepatitis B virus transmission-United States. MMWR Morb Mortal Wkly Rep. 1995;44:574-575.
6. Centers for Disease Control and Prevention. Achievements in public health: hepatitis B vaccination-United States, 1982-2002. MMWR Morb Mortal Wkly Rep. 2002;51:563.
7. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis. 2002;185:713-719.
8. Mast EE, Williams IT, Alter MJ, Margolis HS. Hepatitis B vaccination of adolescent and adult high-risk groups in the United States. Vaccine. 1998;16:S27-S29.
9. Rich JD, Ching CG, Lally MA, et al. A review of the case for hepatitis B vaccination of high-risk adults. Am J Med. 2003;114:316-318.
10. Hagan H. Vaccination could improve overall health in a high risk population. West J Med. 2000;172:21.
11. Stein MD, Friedmann P. Need for medical and psychosocial services among injection drug users: a comparative study of needle exchange and methadone maintenance. Am J Addict. 2002;11:262-270.
12. Kuo I, Brady J, Butler C, et al. Feasibility of referring drug users from a needle exchange program into an addiction treatment program: experience with a mobile treatment van and LAAM maintenance. J Subst Abuse Treat. 2003;24:67-74.
13. Riley ED, Safaeian M, Strathdee SA, Brooner RK, Beilenson P, Vlahov D. Drug user treatment referrals and entry among participants of a needle exchange program. Subst Use Misuse. 2002;37:1869-1886.
14. Heimer R. Can syringe exchange serve as a conduit to substance abuse treatment? J Subst Abuse Treat. 1998;15:183-191.
15. Pollack HA, Khoshnood K, Blankenship KM, Altice FL. The impact of needle exchange-based health services on emergency department use. J Gen Intern Med. 2002; 17:341-348.
16. Grau LE, Arevalo S, Catchpool C, Heimer R. Expanding harm reduction services through a wound and abscess clinic. Am J Public Health. 2002;92:1915-1917.
17. Liebman J, Pat Lamberti M, Altice F. Effectiveness of a mobile medical van in providing screening services for STDs and HIV. Public Health Nurs. 2002;19:345-353.
18. Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health. 2003;80:416-427.
19. Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin Infect Dis. 2004; 38 suppl 5:5376-5387.
20. McGarry KA, Stein MD, Clarke JG, Friedmann PD. Utilization of preventive health services by HIV-seronegative injection drug users. J Addict Dis. 2002;21:93-102.
21. Kaplan EH, Heimer R. HIV prevalence among intravenous-drug-users-model- based estimates from New Haven's legal needle exchange. J Acquir Immune Defic Syndr. 1992;5:163-169.
22. Scrimenti K. Homeless Count 2003: New Haven Final Report. September 2003. Available at: http://www.theconsultationcenter.org/Homeless%20Count.pdf. Accessed February 21, 2004.
23. State of Connecticut. Department of Economic and Community Development, Connecticut Town Profiles 1998-1999. Available at: http://www.state.ct.us/ecd/ research/townprof/index.html. Accessed February 21, 2004.
24. Connecticut Department of Public Health. Connecticut HIV/AIDS statistics through June 30, 2002. Available at: http://www.dph.state.ct.us/BCH/ infectiousdise/aids_case_data.htm. Accessed February 21, 2004.
25. Heimer R, Kaplan EH, O'Keefe E, Khoshnood K, Altice FL. Three years of needle exchange in New Haven: what have we learned? AIDS Public Policy J. 1994;9:59-74.
26. Salomon N, Perlman DC, Friedmann P, Ziluck V, Des Jarlais DC. Prevalence and risk factors for positive tuberculin skin tests among active drug users at a syringe exchange program. Int J Tuberc Lung Dis. 2000;4:47-54.
27. Stancliff S, Salomon N, Perlman DC, Russell PC. Provision of influenza and pneumococcal vaccines to injection drug users at a syringe exchange. J Subst Abuse Treat. 2000;18:263-265.
28. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655-661.
29. Gyarmathy VA, Neaigus A, Miller M, Friedman SR, Des Jarlais DC. Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users. J Acquir Immune Defic Syndr. 2002;30:448-456.
30. Quaglio GL, Lugoboni F, Pajusco B, et al. Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clin Infect Dis. 2003;37:33-40.
31. Santana Rodriguez OE, Male Gil ML, Hernandez Santana JF, Liminana Canal JM, Martin Sanchez AM. Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. Eur J Epidemiol. 1998;14:555-561.
32. Broers B, Junet C, Bourquin M, Deglon JJ, Perrin L, Hirschel B. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS. 1998;12:2059-2066.
33. Carter H, Robinson G, Hanlon C, Hailwood C, Massarotto A. Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. N Z Med J. 2001;114:324-326.
34. Hess G, Rossol S, Voth R, Cheatham-Speth D, Clemens R, Meyer zum Buschenfelde KH. Active immunization of homosexual men using a recombinant hepatitis B vaccine. J Med Virol. 1989;29:229-231.
35. Des Jarlais DC, Fisher DG, Newman JC, et al. Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program. Am J Public Health. 2001;91:1791-1792.
36. Seal KH, Edlin BR. Risk of hepatitis B infection among young injection drug users in San Francisco: opportunities for intervention. West J Med. 2000;172:16-20.
37. Zeldis JB, Jain S, Kuramoto IK, et al. Seroepidemiology of viral infections among intravenous drug users in Northern California. West J Med. 1992;156:30-35.
38. Lifson AR, Halcon LL. Substance abuse and high-risk needle-related behaviors among homeless youth in Minneapolis: implications for prevention. J Urban Health. 2001;78:690-698.
39. Lum PJ, Ochoa KC, Hahn JA, et al. Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study. Am J Public Health. 2003;93:919-923.
40. Sexually transmitted diseases treatment guidelines. 2002. Centers for Disease Control Prevention. MMWR Recomm Rep. 2002;51:1-78.
41. Andre FE, Path FRC. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med. 1989;87:145-205.
42. Wright NM, Campbell TL, Tompkins CN. Comparison of conventional and accelerated hepatitis B immunisation schedules for homeless drug users. Commun Dis Public Health. 2002;5:324-326.
43. Carlsson T, Struve J, Sonnerborg A, Weiland O. The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. Scand J Infect Dis. 1999;31:93-95.
44. Quaglio G, Talamini G, Lugoboni F, et al. Compliance with hepatitis B vaccination in. 1175 heroin users and risk factors associated with lack of vaccine response. Addiction. 2002;97:985-992.
45. Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:175-176.
46. Paone D, Des Jarlais DC, Gangloff R, Milliken J, Friedman SR. Syringe exchange: HIV prevention, key findings, and future directions. Int J Addict. 1995;30:1647-1683.
47. Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet. 1996;348:987-991.
48. Friedman SR, Chapman TF, Perlis TE, et al. Similarities and differences by race/ethnicity in changes of HIV seroprevalence and related behaviors among drug injectors in New York City, 1991-1996. J Acquir Immune Defic Syndr. 1999;22:83-91.
49. Monterroso ER, Hamburger ME, Vlahov D, et al. Prevention of HIV infection in street-recruited injection drug users. The Collaborative Injection Drug User Study (CIDUS). J Acquir Immune Defic Syndr. 2000;25:63-70.
50. Khoshnood K, Kaplan EH, Heimer R. 'Dropouts' or 'drop-ins'? Client retention and participation in New Haven's needle exchange program. Public Health Report. 1995;110:462-A66.
51. Rockwell R, Des Jarlais DC, Friedman SR, Perlis TE, Paone D. Geographic proximity, policy and utilization of syringe exchange programmes. AIDS Care. 1999;11:437-442.
52. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:47-58.
53. Mostashari F, Riley E, Selwyn PA, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J. Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:341-348.
54. O'Connor PG, Molde S, Henry S, Shockcor WT, Schottenfeld RS. Human immunodeficiency virus infection in intravenous drug users: a model for primary care. Am J Med. 1992;93:382-386.
55. Borg L, Khuri E, Wells A et al. Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination. Addiction. 1999;94:489-493.
56. van Steenbergen JE. Results of an enhanced-outreach programme of hepatitis B vaccination in the Netherlands (1998-2000) among men who have sex with men, hard drug users, sex workers and heterosexual persons with multiple partners. J Hepatol. 2002;37:507-513.